Cargando…

Development and validation of a prognostic score predicting recurrence in resected combined hepatocellular cholangiocarcinoma

Purpose: To develop and validate a decision aid to help make individualized estimates of tumor recurrence for patients with resected combined hepatocellular cholangiocarcinoma (CHC). Patients and methods: Risk factors of recurrence were identified in the derivation cohort of 208 patients who underwe...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Meng-Xin, Luo, Liu-Ping, Liu, Wei-Ren, Deng, Wei, Yin, Jia-Cheng, Jin, Lei, Jiang, Xi-Fei, Zhou, Yu-Fu, Qu, Wei-Feng, Tang, Zheng, Wang, Han, Tao, Chen-Yang, Fang, Yuan, Qiu, Shuang-Jian, Zhou, Jian, Liu, Jing-Feng, Fan, Jia, Shi, Ying-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6556465/
https://www.ncbi.nlm.nih.gov/pubmed/31239773
http://dx.doi.org/10.2147/CMAR.S195964
_version_ 1783425330454724608
author Tian, Meng-Xin
Luo, Liu-Ping
Liu, Wei-Ren
Deng, Wei
Yin, Jia-Cheng
Jin, Lei
Jiang, Xi-Fei
Zhou, Yu-Fu
Qu, Wei-Feng
Tang, Zheng
Wang, Han
Tao, Chen-Yang
Fang, Yuan
Qiu, Shuang-Jian
Zhou, Jian
Liu, Jing-Feng
Fan, Jia
Shi, Ying-Hong
author_facet Tian, Meng-Xin
Luo, Liu-Ping
Liu, Wei-Ren
Deng, Wei
Yin, Jia-Cheng
Jin, Lei
Jiang, Xi-Fei
Zhou, Yu-Fu
Qu, Wei-Feng
Tang, Zheng
Wang, Han
Tao, Chen-Yang
Fang, Yuan
Qiu, Shuang-Jian
Zhou, Jian
Liu, Jing-Feng
Fan, Jia
Shi, Ying-Hong
author_sort Tian, Meng-Xin
collection PubMed
description Purpose: To develop and validate a decision aid to help make individualized estimates of tumor recurrence for patients with resected combined hepatocellular cholangiocarcinoma (CHC). Patients and methods: Risk factors of recurrence were identified in the derivation cohort of 208 patients who underwent liver resection between 1995 and 2014 at Zhongshan Hospital to develop a prediction score. The model was subsequently validated in an external cohort of 101 CHC patients using the C concordance statistic and net reclassification index (NRI). Results: On multivariate analysis, five independent predictors associated with tumor recurrence were identified, including sex, γ-glutamyl transferase, macrovascular invasion, hilar lymphoid metastasis and adjuvant transcatheter arterial chemoembolization. The prediction score was constructed using these 5 variables, with scores ranging from 0 to 5. A patient with a score of 0 had a predicted 1- and 5-year recurrence risk of 11.1% and 22.2%, respectively. In the validation cohort, the NRIs of prediction score vs American Joint Committee on Cancer 7(th) TNM staging system at 1-year and 5-year were 0.185 (95% CI, 0.090–0.279, P<0.001) and 0.425 (95% CI, 0.044–0.806, P=0.03), respectively. Conclusion: Our developed and validated prediction score might be a simple and reliable method in postoperative CHC patients and help clinicians identify candidates who may benefit from future adjuvant therapies.
format Online
Article
Text
id pubmed-6556465
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-65564652019-06-25 Development and validation of a prognostic score predicting recurrence in resected combined hepatocellular cholangiocarcinoma Tian, Meng-Xin Luo, Liu-Ping Liu, Wei-Ren Deng, Wei Yin, Jia-Cheng Jin, Lei Jiang, Xi-Fei Zhou, Yu-Fu Qu, Wei-Feng Tang, Zheng Wang, Han Tao, Chen-Yang Fang, Yuan Qiu, Shuang-Jian Zhou, Jian Liu, Jing-Feng Fan, Jia Shi, Ying-Hong Cancer Manag Res Original Research Purpose: To develop and validate a decision aid to help make individualized estimates of tumor recurrence for patients with resected combined hepatocellular cholangiocarcinoma (CHC). Patients and methods: Risk factors of recurrence were identified in the derivation cohort of 208 patients who underwent liver resection between 1995 and 2014 at Zhongshan Hospital to develop a prediction score. The model was subsequently validated in an external cohort of 101 CHC patients using the C concordance statistic and net reclassification index (NRI). Results: On multivariate analysis, five independent predictors associated with tumor recurrence were identified, including sex, γ-glutamyl transferase, macrovascular invasion, hilar lymphoid metastasis and adjuvant transcatheter arterial chemoembolization. The prediction score was constructed using these 5 variables, with scores ranging from 0 to 5. A patient with a score of 0 had a predicted 1- and 5-year recurrence risk of 11.1% and 22.2%, respectively. In the validation cohort, the NRIs of prediction score vs American Joint Committee on Cancer 7(th) TNM staging system at 1-year and 5-year were 0.185 (95% CI, 0.090–0.279, P<0.001) and 0.425 (95% CI, 0.044–0.806, P=0.03), respectively. Conclusion: Our developed and validated prediction score might be a simple and reliable method in postoperative CHC patients and help clinicians identify candidates who may benefit from future adjuvant therapies. Dove 2019-06-05 /pmc/articles/PMC6556465/ /pubmed/31239773 http://dx.doi.org/10.2147/CMAR.S195964 Text en © 2019 Tian et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Tian, Meng-Xin
Luo, Liu-Ping
Liu, Wei-Ren
Deng, Wei
Yin, Jia-Cheng
Jin, Lei
Jiang, Xi-Fei
Zhou, Yu-Fu
Qu, Wei-Feng
Tang, Zheng
Wang, Han
Tao, Chen-Yang
Fang, Yuan
Qiu, Shuang-Jian
Zhou, Jian
Liu, Jing-Feng
Fan, Jia
Shi, Ying-Hong
Development and validation of a prognostic score predicting recurrence in resected combined hepatocellular cholangiocarcinoma
title Development and validation of a prognostic score predicting recurrence in resected combined hepatocellular cholangiocarcinoma
title_full Development and validation of a prognostic score predicting recurrence in resected combined hepatocellular cholangiocarcinoma
title_fullStr Development and validation of a prognostic score predicting recurrence in resected combined hepatocellular cholangiocarcinoma
title_full_unstemmed Development and validation of a prognostic score predicting recurrence in resected combined hepatocellular cholangiocarcinoma
title_short Development and validation of a prognostic score predicting recurrence in resected combined hepatocellular cholangiocarcinoma
title_sort development and validation of a prognostic score predicting recurrence in resected combined hepatocellular cholangiocarcinoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6556465/
https://www.ncbi.nlm.nih.gov/pubmed/31239773
http://dx.doi.org/10.2147/CMAR.S195964
work_keys_str_mv AT tianmengxin developmentandvalidationofaprognosticscorepredictingrecurrenceinresectedcombinedhepatocellularcholangiocarcinoma
AT luoliuping developmentandvalidationofaprognosticscorepredictingrecurrenceinresectedcombinedhepatocellularcholangiocarcinoma
AT liuweiren developmentandvalidationofaprognosticscorepredictingrecurrenceinresectedcombinedhepatocellularcholangiocarcinoma
AT dengwei developmentandvalidationofaprognosticscorepredictingrecurrenceinresectedcombinedhepatocellularcholangiocarcinoma
AT yinjiacheng developmentandvalidationofaprognosticscorepredictingrecurrenceinresectedcombinedhepatocellularcholangiocarcinoma
AT jinlei developmentandvalidationofaprognosticscorepredictingrecurrenceinresectedcombinedhepatocellularcholangiocarcinoma
AT jiangxifei developmentandvalidationofaprognosticscorepredictingrecurrenceinresectedcombinedhepatocellularcholangiocarcinoma
AT zhouyufu developmentandvalidationofaprognosticscorepredictingrecurrenceinresectedcombinedhepatocellularcholangiocarcinoma
AT quweifeng developmentandvalidationofaprognosticscorepredictingrecurrenceinresectedcombinedhepatocellularcholangiocarcinoma
AT tangzheng developmentandvalidationofaprognosticscorepredictingrecurrenceinresectedcombinedhepatocellularcholangiocarcinoma
AT wanghan developmentandvalidationofaprognosticscorepredictingrecurrenceinresectedcombinedhepatocellularcholangiocarcinoma
AT taochenyang developmentandvalidationofaprognosticscorepredictingrecurrenceinresectedcombinedhepatocellularcholangiocarcinoma
AT fangyuan developmentandvalidationofaprognosticscorepredictingrecurrenceinresectedcombinedhepatocellularcholangiocarcinoma
AT qiushuangjian developmentandvalidationofaprognosticscorepredictingrecurrenceinresectedcombinedhepatocellularcholangiocarcinoma
AT zhoujian developmentandvalidationofaprognosticscorepredictingrecurrenceinresectedcombinedhepatocellularcholangiocarcinoma
AT liujingfeng developmentandvalidationofaprognosticscorepredictingrecurrenceinresectedcombinedhepatocellularcholangiocarcinoma
AT fanjia developmentandvalidationofaprognosticscorepredictingrecurrenceinresectedcombinedhepatocellularcholangiocarcinoma
AT shiyinghong developmentandvalidationofaprognosticscorepredictingrecurrenceinresectedcombinedhepatocellularcholangiocarcinoma